文献速递糖尿病

eNAMPT是减轻2型糖尿病冠状动脉微血管疾病的新治疗靶点

eNAMPT is a novel therapeutic target for mitigation of coronary microvascular disease in type 2 diabetes.
PubMed 文献 · Diabetologia · 2024-06-19

本研究在2型糖尿病小鼠模型中探讨细胞内和细胞外烟酰胺磷酸核糖转移酶(i/eNAMPT)在冠状动脉微血管疾病(CMD)中的作用。糖尿病小鼠冠状动脉血流速度储备(CFVR)显著降低,eNAMPT水平升高;通过Nampt+/-杂合子、eNAMPT中和单克隆抗体或NAMPT酶抑制剂FK866抑制i/eNAMPT可显著改善CFVR。结果表明i/eNAMPT表达增加促进糖尿病冠状动脉微血管功能障碍,抑制eNAMPT可能是CMD的新治疗策略。

要点

  • 糖尿病小鼠CFVR显著低于对照,eNAMPT血浆水平及CEC表达显著高于对照。
  • Nampt+/-杂合糖尿病小鼠CFVR明显改善,伴左心室毛细血管密度增加和冠状动脉EDR增强。
  • FK866或eNAMPT中和单抗显著增加糖尿病小鼠CFVR,eNAMPT单抗上调血管生成和EDR相关基因表达。

核心结论

  • 数据表明i/eNAMPT表达增加促进糖尿病冠状动脉微血管功能障碍的发生,为抑制eNAMPT作为糖尿病CMD的新型有效治疗策略提供了有力支持。

研究设计与样本

  • 研究采用可诱导的2型糖尿病小鼠模型,通过单次低剂量链脲佐菌素(75 mg/kg,腹腔注射)联合高脂饮食16周建立。
  • 通过Nampt+/-杂合小鼠、长期给予eNAMPT中和单克隆抗体或使用NAMPT酶抑制剂FK866,评估抑制i/eNAMPT对心脏内皮细胞(CEC)功能的体内效应。

主要发现

  • 糖尿病野生型小鼠CFVR显著低于对照野生型小鼠,糖尿病小鼠eNAMPT血浆水平或CEC表达显著高于对照小鼠。
  • 与糖尿病野生型小鼠相比,糖尿病Nampt+/-杂合小鼠CFVR明显改善,伴左心室毛细血管密度增加和冠状动脉内皮依赖性舒张(EDR)增强。
  • FK866或eNAMPT中和单抗显著增加糖尿病小鼠CFVR,eNAMPT单抗上调糖尿病小鼠CEC中血管生成和EDR相关基因表达。
  • eNAMPT或NAD+处理显著降低CEC迁移和冠状动脉EDR,部分与线粒体活性氧产生增加有关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Individuals with diabetes are at high risk of cardiovascular complications, which significantly increase morbidity/mortality. Coronary microvascular disease (CMD) is recognised as a critical contributor to the increased cardiac mortality observed in people with diabetes. Therefore, there is an urgent need for treatments that are specific to CMD. eNAMPT (extracellular nicotinamide phosphoribosyltransferase) is a damage-associated molecular pattern and TLR4 ligand, whose plasma levels are elevated in people with diabetes. This study was thus designed to investigate the pathogenic role of intracellular nicotinamide phosphoribosyltransferase (iNAMPT) and eNAMPT in promoting the development of CMD in a preclinical murine model of type 2 diabetes. METHODS: An inducible type 2 diabetic mouse model was generated by a single injection of low-dose streptozocin (75 mg/kg, i.p.) combined with a high-fat diet for 16 weeks. The in vivo effects of i/eNAMPT inhibition on cardiac endothelial cell (CEC) function were evaluated by using Nampt+/- heterozygous mice, chronic administration of eNAMPT-neutralising monoclonal antibody (mAb) or use of an NAMPT enzymatic inhibitor (FK866). RESULTS: As expected, diabetic wild-type mice exhibited significantly lower coronary flow velocity reserve (CFVR), a determinant of coronary microvascular function, compared with control wild-type mice. eNAMPT plasma levels or expression in CECs were significantly greater in diabetic mice than in control mice. Furthermore, in comparison with diabetic wild-type mice, diabetic Nampt+/- heterozygous mice showed markedly improved CFVR, accompanied by increased left ventricular capillary density and augmented endothelium-dependent relaxation (EDR) in the coronary artery. NAMPT inhibition by FK866 or an eNAMPT-neutralising mAb significantly increased CFVR in diabetic mice. Furthermore, administration of the eNAMPT mAb upregulated expression of angiogenesis- and EDR-related genes in CECs from diabetic mice. Treatment with either eNAMPT or NAD+ significantly decreased CEC migration and reduced EDR in coronary arteries, partly linked to increased production of mitochondrial reactive oxygen species. CONCLUSIONS/INTERPRETATION: These data indicate that increased i/eNAMPT expression contributes to the development of diabetic coronary microvascular dysfunction, and provide compelling support for eNAMPT inhibition as a novel and effective therapeutic strategy for CMD in diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Gao L, Ramirez FJ, Cabrera JTO, et al. eNAMPT is a novel therapeutic target for mitigation of coronary microvascular disease in type 2 diabetes. Diabetologia. 2024. PMID: 38898303. doi:10.1007/s00125-024-06201-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。